Safety · HRT
Hormone pellet therapy: risks and why we don't prescribe it
Hormone pellet therapy — subcutaneous implants delivering estrogen or testosterone over 3–6 months — is marketed as convenient. In practice, pellets frequently deliver supraphysiologic doses that cannot be adjusted or removed, and the side effect profile is worse than alternatives. NAMS, the Endocrine Society, and evidence-based menopause specialists do not recommend pellets.
Why pellets fail on safety
- Supraphysiologic doses common (2–4× premenopausal levels)
- Cannot be adjusted or removed for 3–6 months
- Higher rates of virilization in women (acne, hair, voice)
- Elevated hematocrit (blood thickening)
- Uterine bleeding requiring biopsy
- Marketing claims not supported by peer-reviewed evidence
What NAMS says
The North American Menopause Society position statement notes that compounded hormone pellets lack FDA oversight, safety data, and standardized dosing. They should not be considered a first-line therapy.
What Kindr uses instead
Transdermal estradiol, micronized progesterone, and compounded testosterone cream when indicated. Adjustable, evidence-based, and safer.
Frequently asked questions
Why don't you prescribe pellets?
They deliver non-adjustable, often supraphysiologic doses. If side effects occur, you cannot dose down until the pellet dissolves — 3 to 6 months.
What are typical pellet side effects?
Acne, hirsutism (unwanted hair), voice deepening, mood changes, elevated hematocrit, uterine bleeding, and cardiometabolic changes.
Are testosterone pellets FDA approved?
Testopel is FDA approved for hypogonadal men — not women. All female-dosed pellets are compounded and unregulated.
What is the alternative for testosterone?
Compounded testosterone cream (0.5–1 mg/day) — adjustable, physiologic, easy to stop.
What is the alternative for estrogen?
Transdermal estradiol patch, gel, or spray. Adjustable weekly. Same or better efficacy, dramatically better safety.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Explore Kindr Health
Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.